Skip to content

Growing into adulthood with Duchenne Muscular Dystrophy – comparing patient experiences and systems to optimize care

Growing into adulthood with Duchenne Muscular Dystrophy – comparing patient experiences and systems to optimize care - GrowDMD

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00029270
Enrollment
333
Registered
2022-07-26
Start date
2023-07-18
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

DMD is a rare x-linked, genetic disease affecting primarily males with a prevalence of 1/3,500 – 1/9,300. It leads to a progressive muscle weakness due to degeneration of skeletal, smooth and cardiac muscle cells. Diagnosis is often made at around age of 4-5 years. Loss of independent ambulation occurs between the ages of 6 and 13 years. Additional symptoms include the development of joint contractures and scoliosis and – later in the course – respiratory insufficiency and cardiomyopathy. Furthe

Interventions

Group 1: Patients with the Diagnosis DMD (age 15-25 years old), their relatives
and healthcare professionals involved in the transition in Canada, Germany, and Italy. Data will be collected (1) during single-interviews (24 patients and 21 relatives, als well as relevant healthcar

Sponsors

European Joint Programme for Rare Diseases
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
15 Years to 25 Years

Inclusion criteria

Inclusion criteria: Patients with the diagnosis DMD (age 15-25 years old), their relatives and the health care professionals involved in the transition process, living in Canada, Germany, and Italy.

Exclusion criteria

Exclusion criteria: Patients with other diagnosis, siblings; and other professionals (e.g. teacher)

Design outcomes

Primary

MeasureTime frame
In the qualitative comparison, differences and similarities on the level of patients/relatives and care organizations with regard to the implementation of transition guidelines will be examined.

Secondary

MeasureTime frame
In the quantitative part, different quantifiable transition-aspects from the patient-view point will be assessed through standardized questionnaires. Differences between the three different countries as well as between three different age groups will be examined.

Countries

Canada, Germany, Italy

Contacts

Public ContactThorsten Langer

Klinik für Neuropädiatrie und MuskelerkrankungenZentrum für Kinder- und JugendmedizinUNIVERSITÄTSKLINIKUM FREIBURG

thorsten.langer@uniklinik-freiburg.de+49 761 270-43442

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 7, 2026